Literature DB >> 7844523

Sequence polymorphism in the Epstein-Barr virus latent membrane protein (LMP)-2 gene.

P Busson1, R H Edwards, T Tursz, N Raab-Traub.   

Abstract

Latent membrane protein 2A (LMP-2A) is expressed in Epstein-Barr virus transformed B lymphocytes in vitro and has been detected in various types of EBV-associated malignancies. LMP-2A interferes with membrane signal transduction through phosphorylation of its hydrophilic N-terminal domain and binding of the cellular tyrosine kinases encoded by fyn and lyn. In vitro, the domain can block calcium influx and participate in signal transduction inducing cytokine production. These two activities are differently affected by site-directed mutagenesis of potentially phosphorylated amino acid residues. Several potential tyrosine protein kinase recognition motifs have been identified including an antigen recognition motif (ARAM). ARAMs are activated by tyrosine phosphorylation that enables binding of tyrosine protein kinases such as lyn and fyn. To assess the importance of potential sequence variation in natural EBV infection and in tumourigenesis, the sequence of the LMP-2A N-terminal domain was determined in 28 EBV isolates, including 14 fresh tumour isolates. Comparison of the corresponding sequences with the prototype B95 strain indicates that LMP-2 is generally conserved with a few base pair changes resulting in conservative amino acid changes in an occasional isolate. However, five single-base loci were frequently mutated, resulting in three patterns of sequence polymorphism in exon 1 of LMP-2A. The patterns did not segregate with EBV Type 1 or Type 2 and were detected in both lymphoid and epithelial tissues. Four of the most frequent mutations at loci 166627, 166750, 166796 and 166805 (codons 23, 63, 79 and 82) could potentially affect tyrosine protein kinase binding motifs. The pivotal tyrosines (codons 74 and 85) and leucines (codons 77 and 88) of the LMP-2 ARAM were not affected in any of the isolates, suggesting that ARAM function is important for EBV infection in vivo. However, the inter-spacing positions 79 and 82 were distinct in more than 50% of the isolates. These prevalent polymorphisms could influence interaction of the LMP-2 cytoplasmic domain with specific cellular ligand proteins.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7844523     DOI: 10.1099/0022-1317-76-1-139

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  18 in total

1.  Sequence variations of Epstein-Barr virus LMP2A gene in gastric carcinoma in Japan.

Authors:  M Tanaka; Y Kawaguchi; J Yokofujita; M Takagi; Y Eishi; K Hirai
Journal:  Virus Genes       Date:  1999       Impact factor: 2.332

2.  PY motifs of Epstein-Barr virus LMP2A regulate protein stability and phosphorylation of LMP2A-associated proteins.

Authors:  M Ikeda; A Ikeda; R Longnecker
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

Review 3.  Adoptive immunotherapy for Hodgkin's lymphoma.

Authors:  Alana A Kennedy-Nasser; Catherine M Bollard; Cliona M Rooney
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

4.  Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction.

Authors:  S Fruehling; S K Lee; R Herrold; B Frech; G Laux; E Kremmer; F A Grässer; R Longnecker
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

5.  A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy.

Authors:  Christopher P Fox; Tracey A Haigh; Graham S Taylor; Heather M Long; Steven P Lee; Claire Shannon-Lowe; Simon O'Connor; Catherine M Bollard; Javeed Iqbal; Wing C Chan; Alan B Rickinson; Andrew I Bell; Martin Rowe
Journal:  Blood       Date:  2010-07-29       Impact factor: 22.113

6.  Conservation of Epstein-Barr virus cytotoxic T-cell epitopes in posttransplant lymphomas: implications for immune therapy.

Authors:  Qian Tao; Jie Yang; He Huang; Lode J Swinnen; Richard F Ambinder
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

7.  Epstein-Barr virus latent membrane protein 2 associates with and is a substrate for mitogen-activated protein kinase.

Authors:  C G Panousis; D T Rowe
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

8.  Multi-transmembrane protein K15 of Kaposi's sarcoma-associated herpesvirus targets Lyn kinase in the membrane raft and induces NFAT/AP1 activities.

Authors:  Nam-Hyuk Cho; Young-Ki Choi; Joong-Kook Choi
Journal:  Exp Mol Med       Date:  2008-10-31       Impact factor: 8.718

9.  Epstein-barr virus nuclear antigen 1 sequences in endemic and sporadic Burkitt's lymphoma reflect virus strains prevalent in different geographic areas.

Authors:  G Habeshaw; Q Y Yao; A I Bell; D Morton; A B Rickinson
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

10.  Epstein-Barr virus latent membrane protein 1 genetic variability in peripheral blood B cells and oropharyngeal fluids.

Authors:  Nicholas Renzette; Mohan Somasundaran; Frank Brewster; James Coderre; Eric R Weiss; Margaret McManus; Thomas Greenough; Barbara Tabak; Manuel Garber; Timothy F Kowalik; Katherine Luzuriaga
Journal:  J Virol       Date:  2014-01-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.